Quarterly report [Sections 13 or 15(d)]

Stock-Based Compensation

v3.25.1
Stock-Based Compensation
 3 Months Ended
Mar. 31, 2025
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation Stock-Based Compensation 
The Company grants stock-based awards under its 2024 Incentive Stock Plan (the “2024 Plan”). The shares issued as a result of stock-based compensation transactions generally have been funded with the issuance of new shares of the Company’s common stock. The Company may grant the following types of incentive awards under the 2024 Plan: (i) non-qualified stock options; (ii) incentive stock options; (iii) stock appreciation rights; (iv) restricted stock; and (v) restricted stock units. Each award granted under the 2024 Plan is subject to an award agreement that incorporates, as applicable, the exercise price, the term of the award, the periods of restriction, the number of shares to which the award pertains and such other terms and conditions as the plan committee determines. Awards granted under the 2024 Plan are classified as equity awards, which are recorded in stockholders’ equity in the Company’s consolidated balance sheets. Through March 31, 2025, the Company has granted under the 2024 Plan (i) non-qualified stock options; (ii) incentive stock options; and (iii) restricted stock. There were no stock appreciation rights and restricted stock units granted under the 2024 Plan as of March 31, 2025.
Stock Options
The Company’s closing price on the date of grant is the basis of fair value of its common stock used in determining the value of share-based awards. To the extent the value of the Company’s share-based awards involves a measure of volatility, the Company uses available historical volatility of the Company’s common stock over a period of time corresponding to the expected stock option term. The Company uses the simplified method to calculate the expected term of stock option grants to employees as the Company does not have sufficient comparable historical exercise data to provide a reasonable basis upon which to estimate the expected term of stock options granted to employees. Accordingly, the expected life of the options granted is based on the average of the vesting term, which is generally four years and the contractual term, which is generally ten years. The Company will
continue to evaluate the appropriateness of utilizing such method. The risk-free interest rate is based on United States Treasury yields in effect at the date of grant for periods corresponding to the expected stock option term. Forfeitures are estimated based on historical and forecasted turnover, which is approximately 5%.
The Company did not grant options during the three months ended March 31, 2025, and 2024.
The information below summarizes the stock option activity for three months ended March 31, 2025:
Number of
Shares		 Weighted
Average
Exercise
Price		 Weighted
Average
Remaining
Contractual Life
(Years)
Outstanding at December 31, 2024 281,977  $ 11.80  3.3
Granted —  — 
Exercised (3,000) 3.07 
Forfeited (432) 45.39 
Expired (64,470) 16.94 
Outstanding at March 31, 2025 214,075  $ 10.30  3.9
Exercisable at March 31, 2025 175,695  $ 10.13  2.6
For the three months ended March 31, 2025, and 2024, stock-based compensation expense for stock options was $21,641 and $54,739, respectively.
Restricted Stock
Restricted stock awards granted to employees generally vest in four equal annual installments, although on March 5, 2024, the Company granted 29,454 shares of restricted stock as part of a special award to certain executive employees that vested in one installment on the first anniversary of the grant. Restricted stock awards granted to non-employee directors typically vest in full one year after the date of grant.
The information below summarizes the restricted stock activity for the three months ended March 31, 2025:
Restricted Stock Awards Shares Weighted Average
Grant-Date Fair
Value per Award
Non-vested at December 31, 2024 305,982  $ 11.97 
Granted 187,828  10.79 
Vested (70,587) 12.34 
Forfeited (39,263) 11.53 
Non-vested at March 31, 2025 383,960  $ 11.37 
For the three months ended March 31, 2025, and 2024, stock-based compensation expense for restricted stock awards was $272,300 and $438,656, respectively.